Obesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment

NCT06411210 · Recruiting

Last updated 2026-05-28

This clinical trial is testing whether a GLP-1 analogue medication can help reduce visceral fat in adults with both type 1 diabetes and obesity over a 12-month period.

Status Recruiting Currently enrolling participants.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, double-blind basic-science study

Participants 54 people Planned (estimated).

Who can join Ages 18–30 · all sexes

Timeline Started 2024-07 · est. completion 2028-06

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT06411210 ↗

Description as written by the study sponsor.

More than 40% of young adults with type 1 diabetes (T1D) also have overweight or obesity. Each of these diagnoses increase the risk of adverse cardiovascular events. GLP-1 analogues are anti-obesity medications that are cardioprotective in adults with type 2 diabetes, however evaluation of these agents in people with T1D has been limited to glycemic outcomes. Investigators aim to study the impact of GLP-1 analogue obesity treatment on markers of cardiometabolic risk in young adults with T1D and obesity.

Treatments tested

Semaglutide Pen Injector Drug

Escalated to 2.4mg or max tolerated dose
Placebo Drug

Matched placebo.

Main thing measured	Change in VAT/(VAT+SAT) from baseline to 12 months
Sponsor	Yale University
Conditions studied	Diabetes type1, Obesity
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06411210 ↗